ArticleHistopathology2025
Determinants of oncologic outcomes in high-grade organ-confined prostate cancer after prostatectomy.
Article in Histopathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsIn radical prostatectomy (RP), Grade Group (GG) 4/5 prostate cancer [high-grade prostate cancer (HGPC) hereafter] is often associated with extension beyond the prostate and positive surgical margins. Hence, there is limited information on post-RP outcomes of patients with completely resected HGPC confined to the prostate (pT2). MATERIALS AND
methodsClinical outcomes were assessed in a cohort of patients with pT2 HGPC and negative surgical margins using Kaplan-Meier statistics and Cox regression analysis. RESULTS AND
conclusionFour hundred and seven RPs were initially assessed: 236 (58%) with GG 4 and 171 (42%) with GG 5 prostate cancer (PCa). Survival analysis was performed on subsets of patients with available follow-up (BCR: n = 343, metastases: n = 347) to identify clinicopathologic variables associated with the risk of biochemical recurrence and metastasis. The size of the dominant nodule (cut-off 15 mm) (HR 1.654, 95% CI 1.026-2.667; P = 0.04) and the preoperative PSA level (HR 1.052, 95% CI 1.009-1.097; P = 0.02) were associated with a higher likelihood of BCR on univariate regression analysis, with only preoperative PSA remaining significant when both variables were assessed concurrently (HR 1.051, 95% CI 1.007-1.098; P = 0.02). On univariate Cox regression analysis, the size of the dominant nodule (cut-off: 15 mm; HR 6.315, 95% CI 2.021-19.725; P < 0.01), the presence of large cribriform components (HR 4.375, 95% CI 0.999-19.159; P = 0.05), and LVI (HR 3.808, 95% CI 1.086-13.354; P = 0.04) were associated with the risk of metastasis, but only size remained an independent predictor on multivariate analysis (HR 5.66, 95% CI 1.761-18.191; P < 0.01In p for cut-off of 15 mm).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.